Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Lara Goldstein

Breaking Down Molly: Swiss University Studies How MDMA's Components Might Affect Humans

MindMed’s (NASDAQ:MNMD) recurring collaborator, Prof. Dr. Matthias Liechti of the University Hospital Basel (UHB), will lead a novel Phase 1 clinical trial aiming to compare acute responses to R-MDMA, S-MDMA and MDMA in healthy subjects, which is set to begin on Tuesday.

The study will compare the acute subjective, physiological and endocrine effects of R-MDMA, S-MDMA and racemic -that is, a mixture with equal amounts of its component S and R enantiomers- MDMA in 24 unimpaired volunteers. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.